Bergenbio Asa

Omeros Corporation

Bergen Teknologioverføring As

Affitech Research As

Bergen Teknologioverforing As

Bergebio Asa

Novoplant Gmbh

Sergej Kiprijanov

David Robert Micklem

Linn Nilsson

Lavina Ahmed

Anita Kavlie

Thomas Dudler

Wayne Richard Gombotz

Clark E Tedford

James Brian Parent

Urs Beat Hagemann

Herald Reiersen

James Bradley Lorens

Tone Sandal

Hallvard Haugen

Remko Griep

Lavinia Diana Cicortas Gunnarsson

Didrik Paus

Udo Conrad

Jenny Margareta Karlsson

Linn Hodneland Nilsson

Martin Giersberg

Sigrun Hähnel

Doreen Jahn

The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Anti-axl antagonistic antibodies

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Compositions for inhibiting MASP-2 dependent complement activation

Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Anti-Axl antagonistic antibodies

The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Anti-Axl antibodies

Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Antibodies characterized by their variable sequences/CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Isolated antibodies which bind to CXC chemokine receptor 4

Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.

Anti-EpCAM antibodies

Growing community of inventors

Oslo, Norway

Sergej Kiprijanov